Comparison of 2‐year outcomes between zotarolimus‐eluting and everolimus‐eluting new‐generation cobalt–chromium alloy stents in real‐world diabetic patients |
| |
| Authors: | Tadashi Miyazaki MD Azeem Latib MD Vasileios F. Panoulas MD PhD MRCP Sakiko Miyazaki MD PhD MPH Charis Costopoulos MD Katsumasa Sato MD Toru Naganuma MD Hiroyoshi Kawamoto MD Hiroyuki Daida MD PhD Antonio Colombo MD |
| |
| Affiliation: | 1. Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy;2. Interventional Cardiology Unit, EMO‐GVM Centro Cuore Columbus, Milan, Italy;3. Department of Cardiovascular Medicine, Juntendo University, Tokyo, Japan;4. Physiology and Disease Prevention, National Heart and Lung Institute, Imperial College London, London, United Kingdom |
| |
| Abstract: | Background : To date, it remains unknown whether different types of new‐generation drug‐eluting stents have a differential impact on long‐term outcomes in diabetic patients. Methods and Results : In this historical cohort study (two Italian centers), we analyzed 400 diabetic patients with 553 coronary lesions treated with new‐generation CoCr zotarolimus‐eluting stents (R‐ZES: 136 patients, 196 lesions) or everolimus‐eluting stents (EES: 264 patients, 357 lesions) between October 2006 and August 2012. Primary endpoint was the occurrence of major adverse cardiac events (MACE) over a 2‐year follow‐up period. MACE was defined as all‐cause mortality, any myocardial infarction (MI) and/or target lesion revascularization (TLR). Multivessel revascularization, intervention for restenotic lesion and use of intravascular ultrasound were significantly higher in the R‐ZES group, whereas small stent (≤2.5 mm) deployment was significantly higher in the EES group. At 2‐year follow‐up, there was no significant difference in occurrence of MACE (R‐ZES vs EES: 22.8% vs 18.9%, P = 0.39). Similarly, no significant differences were observed in the composite endpoint of all‐cause mortality/MI (10.0% vs 10.3%, P = 0.86) or TLR (12.4% vs 7.4%, P = 0.11). Adjustment for confounders and baseline propensity‐score matching did not alter the aforementioned associations. Conclusion : After 2 years of follow up similar outcomes (MACE, all‐cause mortality/MI, TLR) were observed in real‐world diabetic patients, including those with complex lesions and patient characteristics, treated with R‐ZES and EES. © 2015 Wiley Periodicals, Inc. |
| |
| Keywords: | diabetes mellitus drug eluting stents (DES) percutaneous coronary intervention (PES) |
|
|
